Your browser doesn't support javascript.
loading
Corrigendum to "Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's antiseizure efficacy" [Neuropharmacology 143 (2018) 186-204].
Brandt, Claudia; Seja, Patricia; Töllner, Kathrin; Römermann, Kerstin; Hampel, Philip; Kalesse, Markus; Kipper, Andi; Feit, Peter W; Lykke, Kasper; Toft-Bertelsen, Trine Lisberg; Paavilainen, Pauliina; Spoljaric, Inkeri; Puskarjov, Martin; MacAulay, Nanna; Kaila, Kai; Löscher, Wolfgang.
Afiliação
  • Brandt C; Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine Hannover, Germany; Center for Systems Neuroscience, Hannover, Germany.
  • Seja P; Program in Molecular and Integrative Biosciences, and Neuroscience Center (HiLife), University of Helsinki, Finland.
  • Töllner K; Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine Hannover, Germany; Center for Systems Neuroscience, Hannover, Germany.
  • Römermann K; Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine Hannover, Germany; Center for Systems Neuroscience, Hannover, Germany.
  • Hampel P; Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine Hannover, Germany; Center for Systems Neuroscience, Hannover, Germany.
  • Kalesse M; Institute for Organic Chemistry, Leibniz Universität Hannover, Germany.
  • Kipper A; Institute for Organic Chemistry, Leibniz Universität Hannover, Germany.
  • Feit PW; Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine Hannover, Germany.
  • Lykke K; Department of Neuroscience, University of Copenhagen, Copenhagen, Denmark.
  • Toft-Bertelsen TL; Department of Neuroscience, University of Copenhagen, Copenhagen, Denmark.
  • Paavilainen P; Program in Molecular and Integrative Biosciences, and Neuroscience Center (HiLife), University of Helsinki, Finland.
  • Spoljaric I; Program in Molecular and Integrative Biosciences, and Neuroscience Center (HiLife), University of Helsinki, Finland.
  • Puskarjov M; Program in Molecular and Integrative Biosciences, and Neuroscience Center (HiLife), University of Helsinki, Finland.
  • MacAulay N; Department of Neuroscience, University of Copenhagen, Copenhagen, Denmark.
  • Kaila K; Program in Molecular and Integrative Biosciences, and Neuroscience Center (HiLife), University of Helsinki, Finland.
  • Löscher W; Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine Hannover, Germany; Center for Systems Neuroscience, Hannover, Germany. Electronic address: wolfgang.loescher@tiho-hannover.de.
Neuropharmacology ; 143: 349-350, 2018 12.
Article em En | MEDLINE | ID: mdl-30343990
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Neuropharmacology Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Neuropharmacology Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Alemanha